Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHActive Not Recruiting
NCT05389449Phase 3Updated Jun 18, 2026
Sponsor: Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
United States, Brazil, Canada, Czechia, France +10 more
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal HyperplasiaCompleted
NCT05299554Phase 3Updated Jun 18, 2026
Sponsor: Immedica Pharma AB
Congenital Adrenal Hyperplasia
United States, France, Japan
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerActive Not Recruiting
NCT06318273Phase 1Updated Jun 17, 2026
Sponsor: AbbVie
Metastatic Castration-Resistant Prostate Cancer
United States, Australia, Canada, France, Israel +2 more
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Active Not Recruiting
NCT04512235Phase 3Updated Jun 17, 2026
Sponsor: Alexion Pharmaceuticals, Inc.
AL Amyloidosis
United States, Australia, Austria, Belgium, Brazil +14 more
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruiting
NCT05786924Phase 1, Phase 2Updated Jun 17, 2026
Sponsor: Institut de Recherches Internationales Servier
Non-small Cell Lung Cancer · Histiocytic Neoplasm · Histiocytosis · BRAF Gene Mutation
United States, Denmark, Hong Kong, Japan, United Kingdom
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric CancerRecruiting
NCT06636435Phase 1Updated Jun 17, 2026
Sponsor: Chiome Bioscience Inc.
Solid Tumors · Hepatocellular Carcinoma (HCC) · Malignant Melanoma · Pediatric Cancer
Japan
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)Completed
NCT03569293Phase 3Updated Jun 17, 2026
Sponsor: AbbVie
Atopic Dermatitis
United States, Argentina, Australia, Bosnia and Herzegovina, Bulgaria +20 more
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.Recruiting
NCT07219615Phase 2Updated Jun 17, 2026
Sponsor: Pfizer
Chronic Spontaneous Urticaria
United States, Bulgaria, Canada, China, Germany +5 more
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active Not Recruiting
NCT05306340Phase 3Updated Jun 17, 2026
Sponsor: Genentech, Inc.
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
United States, Argentina, Germany, Greece, Italy +8 more
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerActive Not Recruiting
NCT04036682Phase 1, Phase 2Updated Jun 17, 2026
Sponsor: Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer · EGFR Exon 20 Mutation
United States, Hong Kong, Italy, Japan, Netherlands +4 more
A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in JapanCompleted
NCT07649252N/AUpdated Jun 17, 2026
Sponsor: Novartis Pharmaceuticals
Melanoma
Japan
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsTerminated
NCT03631199Phase 3Updated Jun 17, 2026
Sponsor: Novartis Pharmaceuticals
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Brazil +36 more
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive Not Recruiting
NCT04594642Phase 1Updated Jun 17, 2026
Sponsor: AstraZeneca
B-cell Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · High-grade B-cell Lymphoma · Follicular Lymphoma
United States, Australia, Japan, South Korea, Taiwan
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)Completed
NCT05850520Phase 3Updated Jun 17, 2026
Sponsor: Bayer
Macular Edema Secondary to Retinal Vein Occlusion
United States, Australia, Austria, Bulgaria, China +22 more
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive Not Recruiting
NCT05349214Phase 3Updated Jun 17, 2026
Sponsor: Novartis Pharmaceuticals
Sjogren Syndrome
United States, Argentina, Australia, Brazil, Bulgaria +21 more
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active Not Recruiting
NCT04961996Phase 3Updated Jun 17, 2026
Sponsor: Hoffmann-La Roche
Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +49 more
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With SpesolimabTerminated
NCT06241573Phase 2, Phase 3Updated Jun 17, 2026
Sponsor: Boehringer Ingelheim
Hidradenitis Suppurativa (HS)
United States, Argentina, Australia, Bulgaria, Canada +9 more
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisActive Not Recruiting
NCT05556096Phase 3Updated Jun 17, 2026
Sponsor: Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis
United States, Argentina, Austria, Brazil, Canada +17 more
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)Active Not Recruiting
NCT05141201N/AUpdated Jun 17, 2026
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
Japan
Special Drug Use-results Surveillance of Tafinlar/MekinistRecruiting
NCT06262919N/AUpdated Jun 17, 2026
Sponsor: Novartis Pharmaceuticals
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Japan
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataActive Not Recruiting
NCT07029711Phase 3Updated Jun 17, 2026
Sponsor: Pfizer
Severe Alopecia Areata
United States, China, Czechia, France, Italy +4 more
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerCompleted
NCT04702880Phase 2Updated Jun 17, 2026
Sponsor: Bristol-Myers Squibb
Extensive-stage Small Cell Lung Cancer
United States, Australia, Belgium, Canada, Greece +6 more
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseaseActive Not Recruiting
NCT04639050Phase 1, Phase 2Updated Jun 16, 2026
Sponsor: Hoffmann-La Roche
Alzheimers Disease
United States, Australia, Canada, Chile, Japan +4 more
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruiting
NCT06764875Phase 3Updated Jun 16, 2026
Sponsor: AstraZeneca
HER2-positive Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
United States, Argentina, Australia, Austria, Belgium +23 more
Special Drug Use Surveillance of Entresto Tablets (Hypertension)Completed
NCT05976230N/AUpdated Jun 16, 2026
Sponsor: Novartis Pharmaceuticals
Hypertension
Japan

Previous page Next page